Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO

Published on : October 3, 2019October 4, 2019 Published by : Chris Frew

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO Bing Yao, surrounded by colleagues and family, rang the opening Nasdaq bell to begin their first day of trading (NASDAQ: VIE). Their journey to IPO [….]

Why Developing Cures for Rare Disease Isn’t So Rare Anymore

Published on : September 3, 2019September 5, 2019 Published by : Steven Surdez

Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, including cell and gene therapy, have fundamentally changed the way life science companies see rare disease drug development. Life science giants like Pfizer, Merck and [….]

Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering

Published on : August 30, 2019August 30, 2019 Published by : Chris Frew

Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering AstraZeneca spinout files for IPO on Nasdaq August 29, 2019 Viela Bio, the AstraZeneca spin-off biotech, has captured the attention of industry insiders since their $250M Series A investment that launched the company in 2018 and they are continuing to do becoming the [….]

Maryland Pavilion to Showcase State’s Thriving Biotech Community at Annual BIO Convention

Published on : May 28, 2019June 3, 2019 Published by : Steven Surdez

BIO 2019 Maryland Pavilion

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

Published on : April 18, 2019April 18, 2019 Published by : Chris Frew

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, 2019 – Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody [….]

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time

Published on : March 13, 2019March 14, 2019 Published by : Steven Surdez

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the [….]

Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead

Published on : November 6, 2018November 14, 2018 Published by : Chris Frew

Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead November 6, 2018 In order: Elizabeth Parsons (Member, Mintz Levin), Aaron Ren (Head of BD and Operations, Viela Bio), Christian Dinneen-Long (Senior Council, AstraZeneca), and Chris Jeffers (Member, Mintz Levin), participate in panel discussion at TEDCO’s Entrepreneur Expo on the Viela Bio Corporate Spinout Story [….]